Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review.
Sudewi Mukaromah KhoirunnisaFithria Dyah Ayu SuryanegaraDidik SetiawanMaarten Jacobus PostmaPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
PROSPERO ID: CRD42021259826.